

Special Issue

Antiviral Drugs in the Time of COVID-19

Message from the Guest Editors

The coronavirus disease 2019 (COVID-19) pandemic caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an unprecedented demand to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and the amount of clinical data generated by the large number of people being infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. This Special Issue is intended to provide the reader with an update on the current status of antiviral treatment in cases of SARS-CoV-2 infection.

Guest Editors

Dr. Francisco Epelde

Internal Medicine Department, Hospital de Sabadell, University Autònoma of Barcelona, 08208 Barcelona, Spain

Dr. Grigore Mihaescu

Department of Microbiology, Immunology and Virology, Faculty of Biology, University of Bucharest, Bucharest, Romania

Deadline for manuscript submissions

closed (30 November 2022)



Pathogens

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/106000

Pathogens
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pathogens@mdpi.com

[mdpi.com/journal/
pathogens](https://mdpi.com/journal/pathogens)





Pathogens

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
pathogens](https://mdpi.com/journal/pathogens)



About the Journal

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics.

Pathogens is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Editor-in-Chief

Prof. Dr. Hinh Ly

Department of Veterinary & Biomedical Sciences, University of Minnesota, Twin Cities, MN, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Infectious Diseases)